Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference.
Leukemias and lymphomas are often characterized by non-random chromosomal translocations that, at the molecular level, induce the activation of specific oncogenes or create novel chimeric genes. They have frequently been regarded as optimal targets for gene-silencing approaches because of the large body of evidence that these single abnormalities directly initiate and maintain the malignant process. Herein, we discuss RNA interference (RNAi)-based approaches for targeting the fusion sites of chromosomal translocations as a future treatment option in leukemias and lymphomas.
Damm-Welk
Christine
C
Pediatric Hematology & Oncology, Children's University Hospital Giessen, Feulgenstr. 12, 35392 Giessen, Germany.
Fuchs
Uta
U
Wössmann
Wilhelm
W
Borkhardt
Arndt
A
D000818:Animals; D004195:Disease Models, Animal; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D007938:Leukemia / Q000235:genetics / Q000628:therapy*; D008223:Lymphoma / Q000235:genetics / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D034622:RNA Interference; D014178:Translocation, Genetic
D015514:Oncogene Proteins, Fusion